
INTRODUCTION: Existing studies link kidney stone treatment to reduced recurrent urinary tract infections (UTIs); however, these studies are limited by their retrospective design and/ or lack of comparison group. The present study assesses a prospective, observational cohort of patients with recurrent UTIs who selected observation or intervention for management of their non-obstructing kidney stones to assess for impact on UTI recurrence. METHODS: From 2020-2025, patients with non-obstructing kidney stones and recurrent UTIs were prospectively enrolled at four centers. After shared decision-making, participants underwent observation or surgical intervention. The primary outcome was UTI recurrence at 12 months post-enrollment, defined as presence of urinary tract symptoms with positive urine culture. The study was powered to detect a 50% reduction in the rate of UTI recurrence between the groups at 12 months. RESULTS: Among 94 patients recruited, followup data at 12 months was available for 21 observation and 46 intervention patients. There were more staghorn stones in the intervention group (15.2% vs. 0%), and the median stone size was larger (13.5 vs. 6 mm). At 12 months, 81% (n=17) in the observation group and 54% (n=25) in the intervention group had a symptomatic UTI recurrence (p=0.06, non-significant). The subgroup (n=17) of stone-free intervention patients had fewer UTI recurrences compared to the observation group (odds ratio 0.12, 95% confidence interval 0.02-0.66). Causation cannot be confirmed due to the observational nature of the study. CONCLUSIONS: For patients with recurrent UTIs and stones, surgical intervention is not associated with decreased risk of UTI recurrence at 12 months overall; however, patients who were stone-free after intervention had significantly fewer UTI recurrences on subgroup analysis.
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated weight loss and cardiometabolic benefits in specific subpopulations. Studies of GLP-1RAs in Canadian end-stage renal disease (ESRD) and kidney transplantation (KT) patients are limited. METHODS: This is a retrospective cohort study of patients evaluated for potential KT at the Vancouver General Hospital (VGH) between January 2014 and August 2024. We analyzed prescription patterns, weight changes, and post-transplant outcomes. RESULTS: At evaluation, 63/2789 (2.3%) patients were on a GLP-1RA. The proportion of GLP-1RA users increased from 0% in 2014-2018, to 0.3% (1/366) in 2019, and 8.7% (20/231) in 2024. There was a mean weight change of-1.82 kg (-1.93%, 95% confidence interval [CI]-3.46 to-0.19, p=0.031; n=26) at six months and-2.50 kg (-2.62%, 95% CI-4.47 to-0.52, p=0.016; n=25) at 12 months post-initiation. Twenty-six patients received a KT and had a median followup of 1.14 (interquartile range [IQR] 0.19-1.79) years. Only 11 patients were on a GLP-1RA at one year post-transplant and had available post-transplant outcome data. No significant differences were detected in estimated glomerular filtration rate (eGFR) (67, IQR 65.5-78 vs. 59, IQR 45-75 mL/min/1.73 m2, p=0.18), graft failure (0% vs. 4.6%, p=1) and mortality (0% vs. 3.0%, p=1) between GLP-1RA users vs. non-users at one year post-KT. CONCLUSIONS: GLP-1RA use in BC's KT evaluation cohort increased since 2019 and was associated with modest weight loss at six and 12 months post-initiation. No significant differences in post-transplant outcomes were detected. This provides preliminary support for GLP-1RAs as a potentially safe weight management strategy for Canadian KT candidates.
INTRODUCTION: The use of sterile gloves in minor outpatient procedures, including vasectomy, remains debated. Performing vasectomies without sterile gloves may lower costs, shorten operative time, and reduce medical waste-important factors for efficiency and sustainability in high-volume practices. We evaluated the risk of post-vasectomy infection in a large cohort of patients who underwent no-scalpel vasectomy performed without sterile gloves. METHODS: We conducted a retrospective review of all vasectomies performed by four physicians using non-sterile gloves from January 1, 2024, to March 31, 2025, across four Canadian outpatient clinics. Infection was defined as an antibiotic prescription within 30 days post-vasectomy recorded in the electronic medical record. We also assessed the effect of attending physician, use of skin glue for wound closure, and appointment duration. Differences were analyzed using Fisher's exact test, with Bonferroni-corrected significance set at p<0.017. RESULTS: Among 4785 vasectomies, four patients (0.08%, 95% confidence interval [CI] 0.03-0.2%) received antibiotics. No significant differences in infection risks were found between physicians (0.08% [2/3, 798], 0.13% [1/756], 0.93% [1/107], 0% [0/124]; p=0.07). Risks were also similar with vs. without skin glue (0.03% vs. 0.3%, p=0.04) and with short (<15 minutes) vs. longer (>30 minutes) appointment durations (0.07% vs. 0.4%, p=0.18). CONCLUSIONS: Post-vasectomy infection risk with non-sterile gloves was very low. These findings support the use of non-sterile gloves for office-based no-scalpel vasectomy. Multicenter, prospective studies are warranted to confirm these findings across diverse clinical settings. Further research should evaluate additional measures, such as skin glue, to reduce infection risk.
INTRODUCTION: While endotracheal tube (ETT) is the traditional airway modality for percutaneous nephrolithotomy (PCNL), the adoption of supine positioning has opened the door for alternative strategies. Laryngeal mask airway (LMA) offers potential advantages, but its safety profile in supine PCNL remains understudied. This study aimed to compare urologic and anesthesia-related outcomes between LMA and ETT in patients undergoing ultrasound-guided supine PCNL. METHODS: In this retrospective study, 206 adult patients undergoing supine PCNL under general anesthesia between March 2023 and June 2024 were analyzed. Patients were grouped by airway modality: LMA (n=156) or ETT (n=50). Exclusion criteria included body mass index (BMI) >35 kg/m2, American Society of Anesthesiologists (ASA) score >= 4, chronic obstructive pulmonary disease (COPD), pregnancy, or incomplete data. Urologic outcomes included intraoperative complications, 30-day complications, and postoperative pain. Anesthesia-related outcomes included hemodynamic instability, post-anesthesia care unit (PACU) stay, airway placement/removal times, and anesthesia-related complications. Outcomes were compared between the groups, and multivariable regression and sensitivity analysis were used to adjust for confounders. RESULTS: Overall complications were significantly lower in the LMA group (13% vs. 28%, p=0.01), and LMA was negatively associated with them in univariable analysis (odds ratio [OR] 0.378, 95% confidence interval [CI] 0.174-0.821, p=0.01). LMA use remained independently associated with a reduced risk of overall anesthetic and urologic complications after ad-hoc adjustments for preoperative risk factors, stone characteristics, and intraoperative factors. Airway placement and removal times were shorter in the LMA group; otherwise, no significant differences were observed in anesthesia-related outcomes. No procedures were aborted or converted due to airway complications. CONCLUSIONS: In our limited study, LMA seems to be a safe and effective alternative to ETT for airway management in appropriately selected patients undergoing supine PCNL. Prospective, randomized studies are needed to confirm these findings.
INTRODUCTION: Where reported at a regional level, kidney cancer incidence and mortality rates are disproportionately higher among First Nations people compared to the non-Indigenous population in Canada; however, national-scale reporting has been limited. This study aimed to examine kidney cancer outcomes among First Nations compared to non-Indigenous adults in Canada from 2006-2015. METHODS: Data were from the 2006 Canadian Census Health and Environmental Cohort (CanCHEC), which linked census respondents to national cancer and mortality databases. Age-standardized incidence and mortality rates were calculated using the 1960 World Standard Population and stratified by sex, age, and region. Relative risks were estimated using Poisson regression. RESULTS: First Nations adults were diagnosed with 445 kidney cancer cases from 2006-2015 and had nearly twice the incidence rate of kidney cancer compared to non-Indigenous adults (relative risk [RR] 1.99, 95% confidence interval [CI] 1.68-2.35). Incidence rates were also elevated by sex, across age groups, and within certain regions. Mortality rates were higher among First Nations adults across all categories, including all-cause, cancer-specific, and kidney cancer mortality, in both sexes and overall. CONCLUSIONS: These findings support concerns raised by First Nations partners about rising kidney cancer incidence and mortality. Interventions targeting risk factors, improved chronic disease management, and access to care are needed. Consistent national data, including stage information, would support better surveillance, early detection, and equitable cancer outcomes.